What is the recommended pharmacologic management for a patient with chronic diastolic heart failure?

Pharmacologic Management of Chronic Diastolic Heart Failure

For chronic diastolic heart failure (HFpEF), treat with an SGLT2 inhibitor (empagliflozin) as first-line therapy, combined with diuretics for symptom relief, and aggressively manage hypertension and other comorbidities.

Primary Pharmacologic Approach

The management of diastolic heart failure differs fundamentally from systolic heart failure, as most neurohormonal antagonists that reduce mortality in systolic dysfunction have failed to show similar benefits in HFpEF. However, recent evidence has changed the landscape:

First-Line Therapy: SGLT2 Inhibitor

• Empagliflozin is now the only medication with robust evidence for reducing heart failure hospitalizations in HFpEF 1
• The EMPEROR-Preserved trial demonstrated a 21% reduction in the composite endpoint of HF hospitalization or cardiovascular death, driven primarily by a 29% reduction in HF hospitalizations
• This benefit occurs regardless of diabetes status
• Note the caveat: The benefit appears greatest in patients with LVEF closer to 50% and diminishes at higher ejection fractions (>62.5%) 1

Symptomatic Management: Diuretics

• Loop diuretics or thiazides for fluid retention and congestion relief 2
• Use cautiously to avoid excessive preload reduction, which can decrease stroke volume and cardiac output in diastolic dysfunction 2
• If GFR <30 mL/min, avoid thiazides except when used synergistically with loop diuretics 2

Secondary Pharmacologic Options

Blood Pressure Control (Essential)

The following agents serve dual purposes—controlling hypertension (a major contributor to diastolic dysfunction) and potentially improving diastolic function:

1. ACE Inhibitors or ARBs

   • May improve relaxation and cardiac distensibility directly 2
   • Long-term benefit through regression of left ventricular hypertrophy 2
   • ARBs preferred if ACE inhibitor causes cough 3, 4

2. Beta-Blockers

   • Indicated for rate control, especially with history of MI, symptomatic CAD, or atrial fibrillation 1
   • Increase diastolic filling time by reducing heart rate 2
   • Important caveat: May contribute to chronotropic incompetence and exercise intolerance in some patients 1

3. Mineralocorticoid Receptor Antagonists (MRAs)

   • Can be considered, though evidence is less robust than in systolic HF 1

Special Situations

If Atrial Fibrillation is Present

• Rate control is mandatory 2
• Digoxin is first choice for symptomatic patients 2
• Beta-blockers or verapamil-type calcium channel blockers to lower heart rate and increase diastolic period 2
• Consider rhythm control strategies per AF guidelines 1

If Concomitant Angina or Hypertension

1. Optimize beta-blocker therapy
2. Consider coronary revascularization if indicated
3. Add long-acting nitrates
4. If unsuccessful, add second-generation dihydropyridine calcium channel blockers 2

Critical Monitoring Parameters

When initiating therapy:

• Check blood pressure, renal function, and electrolytes 1-2 weeks after each dose increment 2
• Recheck at 3 months, then every 6 months 2
• Monitor for excessive diuresis leading to hypotension and reduced cardiac output

Medications to AVOID

1. NSAIDs - can precipitate or worsen heart failure 2, 4
2. Calcium channel blockers (if any systolic dysfunction present) 5
3. Digoxin in sinus rhythm - should be avoided in diastolic HF without atrial fibrillation 4, 6
4. Positive inotropic agents - no role in diastolic dysfunction 5

Algorithmic Treatment Sequence

Step 1: Start empagliflozin (if LVEF closer to 50%)
Step 2: Add loop diuretic if congestion present (titrate carefully)
Step 3: Initiate ACE inhibitor or ARB for blood pressure control and LV remodeling
Step 4: Add beta-blocker if hypertension persists, history of MI, or AF present
Step 5: Consider MRA if symptoms persist despite above therapy
Step 6: Treat specific comorbidities (CAD, diabetes, obesity) aggressively

Key Clinical Pitfall

The most common error is treating diastolic heart failure identically to systolic heart failure. While ACE inhibitors, ARBs, and beta-blockers have mortality benefits in systolic HF, their role in diastolic HF is primarily for blood pressure control and symptom management, not mortality reduction 2. The exception is empagliflozin, which has specific evidence for HFpEF 1. Excessive diuresis is particularly problematic in diastolic dysfunction, as these patients are preload-dependent and can rapidly decompensate with overly aggressive volume removal 2.